Howard C. Coleman, Chief Executive Officer and Chairman

Coleman co-founded Genelex in 1987 and currently serves as Chairman and CEO.

Coleman defines the company’s overall strategy, vision, and place in the pharmacogenetics industry. He is the primary liaison for governmental agencies, clients and partners.

In addition to working at Genelex, Coleman is a Principal at Biotech Trends, LLC. He has also served as a member of the Washington State Board of Health Genetics Task Force and as faculty at the Institute for Science Training and Research.  He has served as expert testimony in multiple legal cases, has written multiple publications, and is an inventor on multiple patents.

Coleman has a BS in Clinical Science and a BA in psychology and studied at the University of Washington and Fred Hutchinson Cancer Research Center.


Tia Aulinskas, PhD, Chief Scientific Officer, Lab Director and Board Member

Dr. Aulinskas co-founded Genelex in 1987 and currently serves as Chief Scientific Officer, Laboratory Director, and Board Secretary. Aulinskas brings more than 30 years of experience in the field of DNA testing.

Dr. Aulinskas leads and manages laboratory science and business operations, financial administration, and product development. Technologies implemented include genotyping, gene sequencing, probe manufacture, contract research services, and FDA product release testing. She has secured all laboratory accreditation and licensing including CAP, CLIA, NYDOH, AABB, ASCLD/LAB, and maintained regulatory compliance with a variety of agencies.

Prior to co-founding Genelex, Dr. Aulinskas served as a senior research fellow in the Pathology Department and Division of Metabolism, Endocrinology and Nutrition at the University of Washington. She has directed laboratory services for multiple national, international, state and federal justice system agencies, biotechnology companies, contract clients, hospitals and individuals.

Dr. Aulinskas holds a doctorate and a BS, cum laude, in medical biochemistry from the University of Cape Town, South Africa and a MS in medical biochemistry from the University of Stellenbosch.


Kristine Ashcraft, Chief Operating Officer

Ashcraft joined Genelex in 2000, and has served in several roles, including Director of Sales and Marketing and Director of Operations, prior to her promotion to Chief Operating Officer in 2010.

Ashcraft is responsible for business development, product design, market share and internal systems. Under her leadership, Genelex sales have more than doubled multiple years in a row.

Prior to joining Genelex, Kristine worked in sales management at an insurance provider and was responsible for establishing training and protocols that helped spur over 2000% growth in three years. Ashcraft has also served in management roles in the non-profit sector.

She obtained her MBA in Entrepreneurship, graduating magna cum laude from the Franklin W. Olin Graduate School of Business at Babson College, and BS in Molecular Biology from the University of New Haven. 


Bob Patterson, M.D., Chief Information Officer

Dr. Patterson joined Genelex in 2007 as Chief Information Officer. Dr. Patterson has been authoring software to improve patient care since 1983. Dr. Patterson has more than 40 years of experience as a psychiatrist and is on the attending staff of McLean Hospital and has an appointment at Harvard Medical School.

Dr. Patterson developed GeneMedRX, which was the first iteration of the YouScript software. Patterson designs, programs and maintains the clinical algorithms that power YouScript.

Prior to working with Genelex, Dr. Patterson was president of Mental Health Connections, Inc. Since 1996, Bob has sat on the subcommittee for Informatics and Decision Support at Harvard’s Institute of Cybermedicine. He has written multiple scientific publications and is an inventor on multiple patents.

Dr. Patterson received his MD from the George Washington University Medical School. He is on the attending staff of McLean Hospital and holds an appointment at Harvard Medical School.


Gregory Alderson, CPA, Executive Vice President and Board Member

Alderson joined Genelex in 2012 as Executive Vice President and has been a member of the Board of Directors since 1987. Alderson has extensive biotechnology and software experience with startups and Fortune 500 companies.

Alderson’s role is to apply entrepreneurial and executive level advisory skills helping guide and foster the Company’s growth.

Prior to Genelex, he served as chairman and CEO of Invizeon Corporation, a provider of advanced communications solutions. Alderson has also served in finance, operations and marketing executive management roles at BioXcelerator, Microsoft, Raima, General Information, Advanced Products & Technologies, Bristol Myers Squibb, and Genetic Systems. Alderson is a former CPA earned while at the Big 4 accounting firm, Deloitte Haskins & Sells (known now as Deloitte).

Alderson earned his MBA from the University of Oregon. He also holds BS degrees in Microbiology and Immunology and in Food Science, both from the University of Washington.


John Nelson, M.D., Medical Director

Nelson joined Genelex in 2013 as Medical Director. Dr. Nelson, MD, MPH is a board-certified OB/GYN with over 30 years of clinical practice and was president of the American Medical Association from 2004-2005.

Dr. Nelson serves as the Genelex’s liaison to physicians, specialists, and organizations, helping to them to understand the clinical benefits of using pharmacogenetics to predict adverse drug event risk and develop protocols for incorporating gene-based prescribing into their workflow.

Dr. Nelson has been in active clinical practice of obstetrics and gynecology since 1975 and currently sees patients at the Health Clinics of Utah. He was a charter member of the Prospective Payment Assessment Commission (now MedPAC) and has recently served on the Advisory Committee to the Director of the National Institutes of Health (NIH). He is currently the Chief Medical Officer at Leavitt Partners in Salt Lake City, Utah.

Dr. Nelson graduated from the University of Utah School of Medicine.


Jessica Oesterheld, M.D., Director of Pharmacologics

Dr. Oesterheld joined Genelex in 2000 and is Director of Pharmacologics. Dr. Oesterheld has decades of experience as a child psychiatrist and is a drug interaction expert since 1992.

Dr. Oesterheld leads the Pharmacy and Therapeutics Committee which updates clinical health, medication and metabolism data.

Prior to working at Genelex, Dr. Oesterheld was medical director of pharmacy management and on the Drug Utilization Committee at MaineCare. She has written a number of books and papers on cytochromes and their development and interactions, the latest being Drug Interactions: Principles for Medical Practice 3rd Edition, which was published by American Psychiatry Press in 2009. She is also an inventor on multiple patents.

Dr. Oesterheld is a graduate of Mount Holyoke College and Tufts Medical School and completed residencies in adult, college, and child and adolescent psychiatry.


Todd Ericson, Director of Sales

Ericson joined Genelex in 2014 and is Director of Sales.

Ericson leads the YouScript internal and external sales teams as well as the customer service team. He is responsible for the acquisition, care and continued positive relationship with customers.

Prior to working at Genelex, Ericson worked as Northwest Area Sales Manager at Myriad Genetic Laboratories of Salt Lake City, Utah, where he led advanced sales teams and was responsible for delivering sales results. Prior to that he worked in various managerial and sales positions at Wyeth Pharmaceuticals in Collegeville, Pennsylvania.

Ericson graduated from the University of Montana with a BS in Business and has earned a CMR certification as a Certified Medical Representative.


Rajeev Pany, Director of Software Engineering

Pany joined Genelex in 2012 as the Director of Software Development.

Pany manages the software development and architect teams, ensuring the accessibility, speed, and utility of the YouScript Personalized Prescribing software.

Prior to Genelex, Pany was Director of Product Development at i2 Technologies and Engineering Director of Healthcare Applications at Net.Orange.

Pany holds a Master of Science degree in mechanical engineering (neural networks/artifical intelligence/optimization) from the University of Texas at Austin, and a Bachelor of Science degree in Mechanical Engineering from Indian Institute of Technology at Madras, India.


Bob Nebel, Director of Finance

Nebel joined Genelex in 2009 as Controller and now serves as Director of Finance.

Nebel leads the financial and human resources teams including oversight of the treasury, tax, internal audit and accounting systems. He is responsible for structuring internal finances to support company growth.

Prior to joining Genelex Nebel worked as controller for Olympic Associates, an architecture and engineering professional services firm, and as an accountant for Barghausen Consulting Engineers, Inc.

Nebel earned his Executive MBA from the University of Washington, a Bachelor of Arts in business from Washington State University, and a Bachelor of Science in accounting from Central Washington State University.


Napoleon “Evans” Calas, Board Member

Calas is a Board Member at Genelex, providing laboratory management advice to the board. His counsel helps guide Genelex business operations.

Calas is currently Vice President of Business Development at Sterling Reference Laboratories in Tacoma, WA, part of Sterling Healthcare Services. Prior to joining Sterling, Evans held executive positions at Dynacare Laboratories, National Health Laboratories/LabCorp, International Clinical Laboratories, and the Hospital Corporation of America.

Calas earned his MBA from Ross School of Business at the University of Michigan with an emphasis on healthcare. He also holds Bachelor of Science degrees from Michigan State University in Zoology and Medical Technology, and a Medical Technologist certification from the William Beaumont Hospital School of Medical Technology & American Society of Clinical Pathologists (ASCP).